Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemonaive NSCLC patients receiving first-line gefitinib monotherapy

Yang, Chih-HsinChih-HsinYangYu, Chong-JenChong-JenYuShih, Jin-YuanJin-YuanShihChang, Yeun-ChungYeun-ChungChangHu, Fu-ChangFu-ChangHuTsai, Meng-ChinMeng-ChinTsaiChen, Kuan-YuKuan-YuChenLin, Zhong-ZheZhong-ZheLinHuang, Ching-JuChing-JuHuangShun, Chia-TungChia-TungShunHuang, Chin-LunChin-LunHuangBean, JamesJamesBeanCheng, Ann-LiiAnn-LiiChengPao, WilliamWilliamPaoYang, Pan-ChyrPan-ChyrYang2011-02-142018-07-122011-02-142018-07-122008-01http://ntur.lib.ntu.edu.tw//handle/246246/224820en-USSpecific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemonaive NSCLC patients receiving first-line gefitinib monotherapy